Current Cancer Drug Targets
Volume 20, 11 Issues, 2020
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Ranking and Category
-
135th of 229 in
Oncology
  |
In the current Pandemic scenario, all articles related to Coronavirus will be processed on a quick track basis, to ensure timely review and publication of much needed research
Contents
Current Cancer Drug Targets, Volume 17 - Number 4
Biography
Review Article
Synthetic Lethal Interactions in Cancer Therapy
, 17(4): 304 - 310Xinwei Geng, Xiaohui Wang, Dan Zhu and Songmin Ying
DOI: 10.2174/1568009616666160426122736
Synthetic Lethal Interactions in Cancer Therapy
Review Article
Chemotherapy and Cardiotoxicity in Hematologic Malignancies
, 17(4): 311 - 324Antonio Stellitano, Roberta Fedele, Santina Barilla, Antonino Iaria, Carmelo Massimiliano Rao and Massimo Martino
DOI: 10.2174/1568009617666161121141607
Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Review Article
The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
, 17(4): 325 - 332Vladimir Stanislavovich Rogovskii
DOI: 10.2174/1568009617666170109110816
The Linkage Between Inflammation and Immune Tolerance: Interfering with Inflammation in Cancer
Review Article
New Candidate Genes for Lack of Sensitivity to Therapy in Pediatric Leukemias
, 17(4): 333 - 343Weronika Bereza, Joanna Szczepanek, Joanna Laskowska and Andrzej Tretyn
DOI: 10.2174/1568009616666161208150148
New Candidate Genes for Lack of Sensitivity to Therapy in Pediatric Leukemias
Review Article
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
, 17(4): 344 - 356Heena Singla, Sourav Kalra, Preeti Kheterpal, Vinod Kumar and Anjana Munshi
DOI: 10.2174/1568009616666161216094026
Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy
Review Article
Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
, 17(4): 357 - 375Bhupinder Kumar, Rakesh Kumar, Ira Skvortsova and Vinod Kumar
DOI: 10.2174/1568009616666160928110818
Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Research Article
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
, 17(4): 376 - 385Ruzhen Zheng, Hao Jiang, Jinhui Li, Xinge Liu and Hongwei Xu
DOI: 10.2174/1568009616666161213141608
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
Research Article
Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
, 17(4): 386 - 401Qiaohua Zhu, Xinfa Yu, Zhi-Wei Zhou, Chengyu Zhou, Xiao-Wu Chen and Shu-Feng Zhou
DOI: 10.2174/1568009616666160630182344
Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)
View Full Editorial Board
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
View Full Editorial Board
About the Journal
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Cancer Drug Targets was launched in 2001. Dr. Ruiwen Zhang serves as the Editor-in-Chief of the journal.
Scopus CiteScore Metrics: 2.75
Advertisement
Webmaster Contact: info@benthamscience.net